New half sandwich-type Ru(ii) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity

2011 ◽  
Vol 40 (37) ◽  
pp. 9533 ◽  
Author(s):  
Ioannis Bratsos ◽  
Camilla Simonin ◽  
Ennio Zangrando ◽  
Teresa Gianferrara ◽  
Alberta Bergamo ◽  
...  
2021 ◽  
Vol 60 (19) ◽  
pp. 14636-14644
Author(s):  
Betty Y. T. Lee ◽  
Matthew P. Sullivan ◽  
Ena Yano ◽  
Kelvin K. H. Tong ◽  
Muhammad Hanif ◽  
...  

2019 ◽  
Vol 116 (10) ◽  
pp. 4090-4098 ◽  
Author(s):  
Yibo Zhao ◽  
Liqian Zhang ◽  
Xu Li ◽  
Yanhui Shi ◽  
Ruru Ding ◽  
...  

Six tetranuclear rectangular metallacycles were synthesized via the [2+2] coordination-driven self-assembly of imidazole-based ditopic donor 1,4-bis(imidazole-1-yl)benzene and 1,3-bis(imidazol-1-yl)benzene, with dinuclear half-sandwichp-cymene ruthenium(II) acceptors [Ru2(µ-η4-oxalato)(η6-p-cymene)2](SO3CF3)2, [Ru2(µ-η4-2,5-dioxido-1,4-benzoquinonato)(η6-p-cymene)2](SO3CF3)2and [Ru2(µ-η4-5,8-dioxido-1,4-naphtoquinonato)(η6-p-cymene)2](SO3CF3)2, respectively. Likewise, three hexanuclear trigonal prismatic metallacages were prepared via the [2+3] self-assembly of tritopic donor of 1,3,5-tri(1H-imidazol-1-yl)benzene with these ruthenium(II) acceptors respectively. Self-selection of the single symmetrical and stable metallacycle and cage was observed although there is the possibility of forming different conformational isomeric products due to different binding modes of these imidazole-based donors. The self-assembled macrocycles and cage containing the 5,8-dioxido-1,4-naphtoquinonato (donq) spacer exhibited good anticancer activity on all tested cancer cell lines (HCT-116, MDA-MB-231, MCF-7, HeLa, A549, and HepG-2), and showed decreased cytotoxicities in HBE and THLE-2 normal cells. The effect of Ru and imidazole moiety of these assemblies on the anticancer activity was discussed. The study of binding ability of these donq-based Ru assemblies with ctDNA indicated that the complex 9 with 180° linear 1 ligand has the highest bonding constantKbto ctDNA.


ChemMedChem ◽  
2021 ◽  
Author(s):  
Kelvin Tong ◽  
Muhammad Hanif ◽  
Sanam Movassaghi ◽  
Matthew P. Sullivan ◽  
James Lovett ◽  
...  

2017 ◽  
Vol 46 (44) ◽  
pp. 15520-15534 ◽  
Author(s):  
JuanJuan Li ◽  
Lihua Guo ◽  
Zhenzhen Tian ◽  
Meng Tian ◽  
Shumiao Zhang ◽  
...  

This class of iridium imino-pyridyl complexes is attractive for development as new anticancer agents.


2018 ◽  
Vol 47 (39) ◽  
pp. 13781-13787 ◽  
Author(s):  
Yujiao Zhang ◽  
Shumiao Zhang ◽  
Zhenzhen Tian ◽  
Juanjuan Li ◽  
Zhishan Xu ◽  
...  

This work demonstrated that the twelve novel half-sandwich IrIII–NHC complexes [(η5-Cpx)Ir(C^O)Cl] were synthesized and explored the mechanism of anticancer action.


2012 ◽  
Vol 41 (24) ◽  
pp. 7358 ◽  
Author(s):  
Ioannis Bratsos ◽  
Elisa Mitri ◽  
Francesco Ravalico ◽  
Ennio Zangrando ◽  
Teresa Gianferrara ◽  
...  

Polyhedron ◽  
2018 ◽  
Vol 152 ◽  
pp. 147-154 ◽  
Author(s):  
Gandhaveeti Rohini ◽  
Jebiti Haribabu ◽  
K.N. Aneesrahman ◽  
Nattamai S.P. Bhuvanesh ◽  
Konakanchi Ramaiah ◽  
...  

1988 ◽  
Vol 59 (02) ◽  
pp. 310-315 ◽  
Author(s):  
P W Koppert ◽  
E Hoegee-de Nobel ◽  
W Nieuwenhuizen

SummaryWe have developed a sandwich-type enzyme immunoassay (EIA) for the quantitation of fibrin degradation products (FbDP) in plasma with a time-to-result of only 45 minutes.* The assay is based on the combination of the specificities of two monoclonal antibodies (FDP-14 and DD-13), developed in our institute. FDP-14, the capture antibody, binds both fibrinogen degradation products (FbgDP) and FbDP, but does not react with the parent fibrin(ogen) molecules. It has its epitope in the E-domain of the fibrinogen molecule on the Bβ-chain between amino acids 54-118. Antibody DD-13 was raised using D-dimer as antigen and is used as a tagging antibody, conjugated with horse-radish peroxidase. A strong positive reaction is obtained with a whole blood clot lysate (lysis induced by tissue-type plasminogen activator) which is used as a standard. The EIA does virtually not detect FbgDP i. e. purified fragments X, Y, or FbgDP generated in vitro in plasma by streptokinase treatment. This indicates that the assay is specific for fibrin degradation products.We have successfully applied this assay to the plasma of patients with a variety of diseased states. In combination with the assay previously developed by us for FbgDP and for the total amount of FbgDP + FbDP (TDP) in plasma, we are now able to study the composition of TDP in patients plasma in terms of FbgDP and FbDP.


The role of vitamin D is implicated in carcinogenesis through numerous biological processes like induction of apoptosis, modulation of immune system inhibition of inflammation and cell proliferation and promotion of cell differentiation. Its use as additional adjuvant drug with cancer treatment may be novel combination for improved outcome of different cancers. Numerous preclinical, epidemiological and clinical studies support the role of vitamin D as an anticancer agent. Anticancer properties of vitamin D have been studied widely (both in vivo and in vitro) among various cancers and found to have promising results. There are considerable data that indicate synergistic potential of calcitriol and antitumor agents. Possible mechanisms for modulatory anticancer activity of vitamin D include its antiproliferative, prodifferentiating, and anti-angiogenic and apoptic properties. Calcitriol reduces invasiveness and metastatic potential of many cancer cells by inhibiting angiogenesis and regulating expression of the key molecules involved in invasion and metastasis. Anticancer activity of vitamin D is synergistic or additive with the antineoplastic actions of several drugs including cytotoxic chemotherapy agents like paclitaxel, docetaxel, platinum base compounds and mitoxantrone. Benefits of addition of vitamin D should be weighed against the risk of its toxicity.


Sign in / Sign up

Export Citation Format

Share Document